Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.080
+0.030 (2.86%)
At close: Dec 26, 2025, 4:00 PM EST
1.070
-0.010 (-0.93%)
After-hours: Dec 26, 2025, 7:53 PM EST
Phio Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
11.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 21.00K | -117.00K | -84.78% |
| Dec 31, 2018 | 138.00K | 123.00K | 820.00% |
| Dec 31, 2017 | 15.00K | -4.00K | -21.05% |
| Dec 31, 2016 | 19.00K | -15.00K | -44.12% |
| Dec 31, 2015 | 34.00K | -37.00K | -52.11% |
| Dec 31, 2014 | 71.00K | -328.00K | -82.21% |
| Dec 31, 2013 | 399.00K | 302.00K | 311.34% |
| Dec 31, 2012 | 97.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PHIO News
- 5 days ago - Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile Corp
- 5 weeks ago - Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress - Newsfile Corp
- 6 weeks ago - Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial - Newsfile Corp